Top ten considerations in the development of parenteral emulsions.
about
Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study.Nanosuspensions: a promising drug delivery strategy.Supercritical fluid technology for enhanced drug delivery.Formulation optimization of a palm-based nanoemulsion system containing levodopa.Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusionPreparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.Brushite foams--the effect of Tween® 80 and Pluronic® F-127 on foam porosity and mechanical propertiesInjectable lipid emulsions-advancements, opportunities and challenges.Overview of drug product development.Controlled-release injectable microemulsions: recent advances and potential opportunities.Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω-3 Polyunsaturated Fatty Acids.Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect.Complexities of particulate matter measurement in parenteral formulations of small-molecule amphiphilic drugsAn improved method to prepare an injectable microemulsion of the galanin-receptor 3 selective antagonist, SNAP 37889, using Kolliphor(®) HS 15.Emulsifiers' composition modulates venous irritation of the nanoemulsions as a lipophilic and venous irritant drug delivery system.Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design.Protective effect of polysaccharides on the stability of parenteral emulsions.Natural oil nanoemulsions as cores for layer-by-layer encapsulation.Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium.Physicochemical stability of parenteral nutrition supplied as all-in-one for neonates.A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development.Synthesis and evaluation of hydroponically alginate nanoparticles as novel carrier for intravenous delivery of propofol.Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution.Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.Screening of Lipid Composition for Scalable Fabrication of Solvent-Free Lipid Microarrays.Nanosuspension Technologies for Delivery of Poorly Soluble DrugsPredicting the optimum compositions of a parenteral nanoemulsion system loaded with azithromycin antibiotic utilizing the artificial neural network model
P2860
Q30903645-69CC9D6E-2565-48CA-8B6B-36271ED16134Q35185309-2A77F900-1395-470F-AACD-24D9326C2401Q35826447-1DDE85D1-2949-4244-BC61-8EECBA8F0912Q36316895-CF69D33A-A86D-4B9C-A56E-DA933C151ADFQ36396516-B888B74A-E4EB-41A6-A549-F8F734FB106EQ36500095-74EAE0FD-7BBF-439B-9B9C-95E01CB8175EQ37120657-24A8C74D-D006-4127-8BAE-F81DE5FAB866Q37257309-CE4CDBCD-549A-4B1C-A77E-3116737309D0Q37803157-34138CD5-B9D4-4C27-A09A-1383ACB7A9D4Q37965423-C68E8E84-9B42-4A5A-BD35-A2700749FBE3Q38170436-CF4EB45F-AFF0-446A-A914-E7A504173B96Q41048612-0558D037-1607-4A3C-828E-32B83B107139Q41788896-8C06A9A1-F8D0-4C9D-B737-DAAE1F56B9C8Q41999900-8DC05874-638E-498B-8566-7B416D0E0C15Q42037122-0B1F92D9-572B-42B2-8CE5-9B5EE733263DQ42942888-94CCEC8E-42B9-4D16-BC15-A05CCF693C80Q43213313-66418EFE-B441-4695-AD79-1D13A275EEFFQ43563703-300FEE35-39F8-4CF2-B5B0-16322826B578Q44877688-CB3AB4E2-F5E9-4FF2-A764-A5208E0303D7Q45953195-57ED25A9-E7C9-4121-B61D-537FA23413BCQ46648328-2A96ED24-97A5-4884-8C62-F30465533F1DQ47422612-1C310545-56A7-423D-B076-344C4CF4A56FQ47739655-DC5EAB8C-0C06-45C6-9C47-E2CC9A96B5A9Q48161831-29761484-93FE-4091-AD30-D58C848126BFQ53769446-DF95B549-6DC5-40FB-A443-F393C21F4274Q55085070-9F3ECD46-D00B-4F33-90B1-C35BEDCFAAD8Q59113220-67270563-A2C9-49E3-865A-5F53B6DD2B24Q59238418-2A0BD675-8E6B-47A8-A1EB-9683221F8EAB
P2860
Top ten considerations in the development of parenteral emulsions.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Top ten considerations in the development of parenteral emulsions.
@ast
Top ten considerations in the development of parenteral emulsions.
@en
type
label
Top ten considerations in the development of parenteral emulsions.
@ast
Top ten considerations in the development of parenteral emulsions.
@en
prefLabel
Top ten considerations in the development of parenteral emulsions.
@ast
Top ten considerations in the development of parenteral emulsions.
@en
P1476
Top ten considerations in the development of parenteral emulsions.
@en
P2093
P304
P356
10.1016/S1461-5347(99)00141-8
P577
1999-04-01T00:00:00Z